Discontinue use at the 1st appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity; if signs of hepatic insufficiency occur, or if persistently abnormal LFTs (3 times ULN) are detected. Consider discontinuation of treatment in case of deterioration in any organ system functions. Not a substitute for ASA for prophylaxis of CV thromboembolic diseases. Not to be given to patients w/ allergy to NSAIDs & those w/ asthma; patients w/ history of CVA, MI, CABG, uncontrolled HTN, CHF NYHA II-IV. Rehydrate patients prior to starting therapy. Risk of upper GI complications (perforations, ulcers or bleedings); fluid retention, oedema & HTN. May be associated w/ risk of thrombotic events (especially MI & stroke). May mask fever & other signs of inflammation. May cause reduction in prostaglandin formation &, secondarily, in renal blood flow, & thereby impair renal function, under conditions of compromised renal perfusion. Reports of ALT &/or AST elevations (approx ≥3 times ULN). Monitor renal function in patients w/ pre-existing significantly impaired renal function, uncompensated heart failure, or cirrhosis. Control HTN before treatment. Monitor BP w/in 2 wk after initiation of treatment & periodically thereafter. If BP rises significantly, consider alternative treatment. Monitor any patient w/ symptoms &/or signs suggesting liver dysfunction, or in whom an abnormal LFT has occurred. Increased risk of GI adverse effects w/ ASA (even at low doses). Caution when co-administering w/ warfarin or other oral anticoagulants. Not to be taken by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Maintain medically appropriate supervision in elderly & in patients w/ renal, hepatic, or cardiac dysfunction. Not recommended in women attempting to conceive.
Sign Out
